Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience
about
Cytotoxic and targeted therapy for hereditary cancersThe role of preoperative systemic treatment in patients with breast cancerIs it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.BRCA1 and BRCA2 mutations and treatment strategies for breast cancer.Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation statusDeregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapyPredictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsWorse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.BRCA mutation testing in determining breast cancer therapy.Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancerSystemic treatment for hereditary cancers: a 2012 update.Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancerDurable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain.Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.Breast Cancer Biomarkers: Utility in Clinical Practice.Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysisSystemic therapy options in BRCA mutation-associated breast cancer.Cancer treatment according to BRCA1 and BRCA2 mutations.Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation.A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study.Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?The axis of progression of disease.Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy?Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.
P2860
Q26739366-35B3F772-F687-4AB8-9793-E1609857398CQ26746034-F82017B2-7143-4ED2-A963-DC4A2C8AA2E1Q28073673-7FDF1464-27A9-4CB3-9478-A04701B73256Q33766513-DC000B64-88AD-4F15-8157-CDB7CB72F35FQ33894431-7515EEF1-A420-4295-98DC-F4F92A766E8AQ34038170-8FF716A7-58EB-4977-A70E-5F45D031B1E6Q34103963-99C7B032-07F5-4483-B001-559C72886A46Q34256001-84A6DC4F-063F-4BA4-81DB-82F1994BDBD5Q34547261-5038EF80-7BA2-46E6-82D3-B26043AFB5C7Q35100315-B2A9E99B-93AF-4F7D-92F2-072DD6DFCA1AQ35224593-3983DD1D-E232-4823-9E26-BADC2BD8F0D7Q35619225-F2A7B199-D4A6-4FD8-839A-0EDAC035E085Q35970359-67E31856-46CC-46E4-848F-5998929A0483Q36599308-CD5A0D81-3C17-4F7F-8675-DA4478D78D24Q36755366-091E931F-4E75-43F9-93E7-6743DD9EA89EQ36814437-EB8E0D3D-B7A4-4FDF-BE1E-C013AFC534D0Q36855453-A3D86234-5979-4936-8291-E38A2EAF2323Q37379689-9173D6F6-A24D-47DD-8C13-A2A5D4DEB209Q37441159-183215FD-8071-4C72-8049-03E697D68B7AQ37583113-BD2DB331-C257-4742-8F05-669DE9D90BD4Q37688494-96D4C1D2-E952-454D-A283-209B4F181F3FQ38025991-36CED0D8-2AF1-46FD-A1AF-246CD27B3AA8Q38028798-2BB5DAC3-DECB-46B6-AFCD-85858FDBFC1DQ38047337-67BC52D9-F22A-4268-8F38-794BBB166686Q38087850-CFE38400-D9B7-43E8-BFDF-3C017B76B8EEQ38151730-2F208071-384C-42F0-8E78-D019E59F3BC5Q38389226-ADDE0147-B3C4-4F1B-AC5F-589F78B6B499Q38727177-5BE7F33D-4614-45CC-818A-CF6A90035A03Q38806371-B40BB1A9-B949-4E12-AC69-B059483D1C74Q38876050-085C55B4-C6F4-4AFF-A785-0A2786E78F33Q39000667-57304B67-9BEB-4EDA-BCAD-381EEA579EFBQ39430849-AC523BC0-792C-4657-9D62-ED5286E7FBF8Q39683758-BE8AC730-7947-4306-B5B7-4F6E5B04879AQ41357330-7BFE2F47-79D7-4AE5-A214-8B9E3984D79EQ42513988-603295E7-0F29-4FD4-B052-568DF6F47F9FQ42670034-C0AB18C3-57D4-4FE9-BB98-DEAA0F9972D5Q42967088-78140027-FD2F-4D54-BACC-C324C19A159CQ43779858-7F87C399-D03B-43DA-9BDE-28E511EF2349Q44732177-E30592D5-9385-40DA-8FD6-1D9FC5C7C1F3Q47107430-C5972507-BA55-42D1-9D5F-C98AA2408C00
P2860
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Response to neoadjuvant system ...... single-institution experience
@en
type
label
Response to neoadjuvant system ...... single-institution experience
@en
prefLabel
Response to neoadjuvant system ...... single-institution experience
@en
P2093
P2860
P356
P1476
Response to neoadjuvant system ...... single-institution experience
@en
P2093
Angelica M Gutierrez Barrera
Constance Albarracin
Deann Atchley
Diane D Liu
Gabriel N Hortobagyi
Jennifer Keating Litton
Lajos Pusztai
Soley Bayraktar
Vicente Valero
P2860
P304
P356
10.1200/JCO.2011.35.2682
P407
P577
2011-09-06T00:00:00Z